Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Moshe Sade-Feldman(Harvard University), Nir Hacohen(Cambridge Hospital), Viktor A. Adalsteinsson(Broad Institute), Michael S. Rooney(BioNTech (United States)), Keren Yizhak(Broad Institute), Ryan J. Sullivan(Dana-Farber Cancer Institute), Genevieve M. Boland(Harvard University), Stacey L. Bjorgaard(Broad Institute), Keith T. Flaherty(Cancer Research Center), Ryan B. Corcoran(Massachusetts General Hospital), Yunxin J. Jiao(Broad Institute), Mehlika Hazar-Rethinam(Massachusetts General Hospital), Michal Barzily-Rokni(Shaare Zedek Medical Center), Hans Vitzthum(Harvard University), Dennie T. Frederick(Broad Institute), Lyn M. Duncan(Harvard University), Donald P. Lawrence(Massachusetts General Hospital), Marc R. Hammond(Harvard University), Emily E. Van Seventer(Massachusetts General Hospital), Jean-Pierre Eliane(Massachusetts General Hospital), Daniel Rosebrock(Broad Institute), Shauna Blackmon(Harvard University), Sachet A. Shukla(Broad Institute), Dan A. Landau(Cornell University), Brandon Nadres(Massachusetts General Hospital), Anat Stemmer‐Rachamimov(Massachusetts General Hospital), Bo Li(Yuhuangding Hospital), Gad Getz(Broad Institute), Jonathan Chen(Broad Institute), Dimitri Livitz(Broad Institute)
Nature Communications
October 20, 2017
Cited by 999


Related Papers